MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2020

    Impact of safinamide on non-motor and motor experiences of daily living: Primary results from the prospective, observational ProGo study

    S. Isaacson, T. Clinch, E. Farbman, R. Pahwa (Boca Raton, FL, USA)

    Objective: Evaluate the effect of safinamide treatment on non-motor and motor experiences of daily living as assessed using the MDS-UPDRS (Parts I nm-EDLand II m-EDL).…
  • MDS Virtual Congress 2020

    Open data sharing of the Parkinson’s Outcomes Project: A global, longitudinal clinical study of over 13,000 people with Parkinson’s disease

    C. Marras, A. Naito, N. Dahodwala, A. Ramirez-Zamora, M. Rafferty, M. Neault, S. Wu, J. Beck, R. DeLeon, T. Davis (Miami, FL, USA)

    Objective: To describe the newly developed Parkinson’s Outcomes Project data sharing policy to the entire research community with a long-term goal of accelerating novel hypothesis…
  • MDS Virtual Congress 2020

    Effects of Nabilone on non-motor symptoms of Parkinson´s Disease: A randomised placebo-controlled study (The NMS-Nab Study)

    M. Peball, F. Krismer, H.G Knaus, A. Djamshidian, M. Werkmann, F. Carbone, P. Ellmerer, B. Heim, K. Marini, D. Valent, G. Goebel, H. Ulmer, H. Stockner, G.K Wenning, R. Stolz, K. Krejcy, W. Poewe, K. Seppi (Innsbruck, Austria)

    Objective: To investigate the effects of the synthetic cannabinoid nabilone for the treatment of non-motor symptoms in Parkinson´s disease (PD) in a controlled fashion. Background:…
  • MDS Virtual Congress 2020

    Resistance Training on Postural Control in Parkinson’s Disease: a Randomized Controlled Trial

    C. Souza, J. Chen, D. Francato, A. Barbosa, M. Voos, E. Barbosa, H. Chien (Sao Paulo, Brazil)

    Objective: To evaluate changes in postural control following RT using static posturography and clinical functional balance tests in Parkinson’s Disease patients Background: Muscle weakness affects…
  • MDS Virtual Congress 2020

    Clinical research of serum uric acid levels in Parkinson’s disease

    J.W Wu, T. Wang (Wuhan, China)

    Objective: To analyzed the variation of uric acid (UA) traits in different Hoehn-Yahr staging in Parkinson's disease (PD). Background: PD is a common neurodegenerative disease.…
  • MDS Virtual Congress 2020

    Patients’ Perceptions of Herbal Medicine for Parkinson’s disease: Thai Perspectives on Cannabis and Mucuna Pruriens

    T. Boonmongkol, O. Phokaewvarangkul, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To determine patients’ perceptions and knowledge of herbal medicine, including medical cannabis (MC) and Mucuna pruriens (MP), for the treatment of Parkinson’s disease (PD) Background: The use…
  • MDS Virtual Congress 2020

    Outcome Profiles in Advanced Parkinson’s Disease Patients Treated With Long-Term Levodopa-Carbidopa Intestinal Gel in a Routine Clinical Practice: Analysis From the COSMOS Study

    A. Fasano, R. García-Ramos, T. Gurevich, R. Jech, S. Femia, J. Parra, M. Simu (Toronto, ON, Canada)

    Objective: To describe the characteristics and outcomes of advanced Parkinson’s disease (PD) patients grouped by treatment duration of levodopa-carbidopa intestinal gel (LCIG, carbidopa-levodopa enteral suspension[CLES],…
  • MDS Virtual Congress 2020

    The Indian Experience of Continuous Dopaminergic therapy with Apomorphine in Parkinson’s Disease

    D. Hoskere Sreenivasa, R. Jayachandran, R. Seetharam, R. Iyer, P. Kukkle (Bangalore, India)

    Objective: A clinical audit of apomorphine pumps – The Indian experience. Background: Continuous dopaminergic therapy remains crucial in the management of moderately advanced Parkinson’s disease…
  • MDS Virtual Congress 2020

    Onset of Drug-Related Adverse Events in Parkinson’s Disease Patients with Motor Fluctuations Treated with Opicapone in Clinical Practice: OPTIPARK Post-Hoc Analysis

    A. Lees, H. Reichmann, J.F Rocha, D. Magalhães, P. Soares-da-Silva (London, United Kingdom)

    Objective: This post-hoc analysis investigated the onset of treatment-emergent adverse events (TEAEs) that were considered at least possibly related to opicapone (OPC) treatment. Background: OPC…
  • MDS Virtual Congress 2020

    A Case of Improved Psychotic Depression and Motor Symptoms in Parkinson’s Disease following Electroconvulsive Therapy (ECT)

    S. Ramesh, J. Ratliff (Philadelphia, PA, USA)

    Objective: To describe a case of motoric, affective, and psychotic symptoms improving in PD following ECT. Background: Parkinson’s disease (PD) is a neurodegenerative disease caused…
  • « Previous Page
  • 1
  • …
  • 51
  • 52
  • 53
  • 54
  • 55
  • …
  • 149
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Patients with Essential Tremor Live Longer than their Relatives
  • #25179 (not found)
  • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley